In breast [13] and prostate cancers [14] as well as in acute myeloid leukemia (AML) [15] a correlation with WT1 expression has been observed, suggesting that PAX2 is a positive transcriptional regulator of WT1. Here, WT1 is linked to prostate carcinoma.